OPEN ACCESS
International Medical Science Research Journal
P-ISSN: 2707-3394, E-ISSN: 2707-3408
Volume 4, Issue 3, No.284-294, March 2024
DOI: 10.51594/imsrj.v4i3.920
Fair East Publishers
Journal Homepage: www.fepbl.com/index.php/imsrj

ENHANCING MEDICATION QUALITY CONTROL IN NIGERIA: A COMPREHENSIVE ANALYSIS OF REGULATORY CHALLENGES AND SOLUTIONS

Michael Alurame Eruaga[1], Esther Oleiye Itua[2], & James Tabat Bature[3]

[1]National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
[2]National Agency for Food and Drug Administration and Control (NAFDAC), Edo State, Nigeria
[3]National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria

Corresponding Author: Michael Alurame Eruaga
Corresponding Author Email: eruagus2@gmail.com

Article Received: 01-01-24 **Accepted**:10-03-24 **Published:** 18-03-24

ABSTRACT

Medication quality control in Nigeria faces multifaceted challenges rooted in regulatory inefficiencies, infrastructural limitations, and systemic inadequacies. This study undertakes a comprehensive analysis of these challenges while proposing pragmatic solutions to bolster the quality control framework in the Nigerian pharmaceutical sector. Drawing upon extensive literature review and expert insights, the research identifies key regulatory challenges impeding effective medication quality control in Nigeria. These challenges encompass inadequate regulatory capacity, inconsistent enforcement mechanisms, rampant substandard and counterfeit medications, and limited access to essential medicines. Additionally, infrastructural deficiencies such as inadequate laboratory facilities and insufficient human resources further exacerbate the problem, leading to compromised patient safety and public health risks. In response to these challenges, the study proposes a multifaceted approach to enhance medication quality control in Nigeria. This includes strengthening regulatory frameworks through

legislative reforms aimed at bolstering enforcement capabilities and harmonizing standards with international best practices. Moreover, improving regulatory capacity through training programs and investment in state-of-the-art laboratory infrastructure is essential to enhance surveillance and detection of substandard medications. Furthermore, fostering collaboration between regulatory agencies, healthcare providers, and pharmaceutical manufacturers is imperative to streamline supply chains and ensure the integrity of medications from production to distribution. Additionally, public awareness campaigns and community engagement initiatives play a pivotal role in empowering consumers to make informed decisions and report instances of substandard medications. By addressing these regulatory challenges and implementing comprehensive solutions, Nigeria can significantly enhance medication quality control, safeguard patient health, and foster a conducive environment for pharmaceutical innovation and growth.

Keywords: Medical, Medication, Drugs, Quality Control, Nigeria, Regulations, Review.

INTRODUCTION

The pharmaceutical sector in Nigeria plays a vital role in providing essential healthcare services to its population of over 200 million people (Oseni, and Oseni, 2017; Obuaku, 2014). With a diverse range of diseases and health challenges, access to quality medications is crucial for ensuring effective treatment and improving public health outcomes. However, the sector grapples with numerous regulatory challenges that impede the assurance of medication quality and safety.

Nigeria's pharmaceutical sector is characterized by a mix of multinational corporations, local manufacturers, and importers catering to the diverse healthcare needs of its populace (NIGERIA'S, 2023). Despite the sector's potential for growth and innovation, it faces significant hurdles such as infrastructural deficiencies, supply chain inefficiencies, and regulatory bottlenecks. These challenges not only hinder the sector's development but also pose risks to public health by compromising the quality and efficacy of medications available to patients.

Medication quality control is paramount for safeguarding public health and ensuring the efficacy and safety of pharmaceutical products (World Health Organization, 2 000; Dixon, 1999.). Poor-quality medications, including substandard and counterfeit drugs, pose grave risks to patients, ranging from treatment failure to adverse reactions and even mortality. Moreover, the proliferation of such medications undermines trust in the healthcare system and hampers efforts to combat diseases effectively. Therefore, robust medication quality control mechanisms are indispensable for maintaining the integrity of the pharmaceutical supply chain and protecting patient well-being (Galletly, and Pinkerton, 2006; World Health Organization, 2017).

Nigeria's medication quality control efforts are hampered by a myriad of regulatory challenges. These include inadequate regulatory capacity, inconsistent enforcement mechanisms, rampant circulation of substandard and counterfeit medications, and limited access to essential medicines. Additionally, infrastructural deficiencies, such as inadequate laboratory facilities and insufficient human resources, further exacerbate the problem. Addressing these challenges requires a comprehensive understanding of their root causes and the development of targeted

solutions to strengthen the regulatory framework and enhance medication quality control processes (Olowofela, et al., 2017; Afolabi, 2013).

In light of these challenges, this study undertakes a comprehensive analysis to identify regulatory bottlenecks hindering medication quality control in Nigeria and proposes pragmatic solutions to address them effectively. By shedding light on these issues and advocating for regulatory reforms, this research aims to contribute to the enhancement of medication quality control practices, thereby advancing public health and fostering sustainable development in Nigeria's pharmaceutical sector.

Regulatory Challenges in Medication Quality Control

Inadequate regulatory capacity poses a significant challenge to medication quality control in Nigeria (Garuba, et al., 2009; Ogbonna, et al., 2015). Regulatory agencies responsible for overseeing the pharmaceutical sector often lack the necessary resources, expertise, and infrastructure to effectively monitor and enforce quality standards (Lawrence, and Woodcock, 2015; Pezzola, and Sweet, 2016; Kohler, et al., 2016). Limited funding and staffing shortages further exacerbate these challenges, leading to gaps in regulatory oversight and enforcement. As a result, many pharmaceutical products may enter the market without undergoing rigorous quality assessments, increasing the risk of substandard or counterfeit medications reaching consumers (Nsimba, 2009; György, 2018).

Inconsistent enforcement mechanisms contribute to the proliferation of substandard and counterfeit medications in Nigeria. Regulatory agencies may face challenges in coordinating efforts across different regions, leading to disparities in enforcement actions and regulatory oversight. Additionally, corruption and lack of accountability within regulatory bodies can undermine enforcement efforts, allowing unscrupulous actors to circumvent regulations and distribute low-quality or counterfeit drugs with impunity. Without consistent and transparent enforcement mechanisms, it becomes difficult to deter illegal practices and ensure compliance with quality standards throughout the pharmaceutical supply chain (Haji, 2023; Liang, and Mackey, 2009).

The widespread circulation of substandard and counterfeit medications poses a grave threat to public health in Nigeria (Akinyandenu, 2013). These products may contain insufficient active ingredients, incorrect dosages, or harmful contaminants, putting patients at risk of treatment failure, adverse reactions, or even death. The prevalence of counterfeit medications is fueled by factors such as weak regulatory oversight, porous borders, and the profitability of illicit drug trade. Despite efforts to combat this issue, including the introduction of regulatory measures and public awareness campaigns, counterfeiters continue to exploit vulnerabilities in the supply chain, making it challenging to eradicate the problem entirely (Buckley, and Gostin, 2013; Mackey, 2013).

Limited access to essential medicines remains a significant barrier to healthcare delivery in Nigeria (Obuaku, 2014; Amadi, and Tsui, 2019.). While medication quality control efforts aim to ensure the availability of safe and effective pharmaceutical products, disparities in access persist due to factors such as geographical remoteness, affordability constraints, and supply chain disruptions. Vulnerable populations, including those in rural areas and underserved communities, are particularly affected by these access barriers, leading to disparities in health outcomes and exacerbating existing inequalities in healthcare access (Douthit, et al., 2015; Cyr, et al., 2019; Diaz, et al., 2021).

Infrastructural deficiencies, including inadequate laboratory facilities and human resources, hinder medication quality control efforts in Nigeria (Wilson, et al., 2018; Efe, 2013). Many regulatory agencies lack the necessary laboratory equipment and trained personnel to conduct comprehensive quality assessments of pharmaceutical products. Furthermore, insufficient investment in infrastructure development and capacity-building initiatives limits the ability of regulatory agencies to effectively monitor and respond to emerging challenges in medication quality control. Without adequate infrastructure and human resources, regulatory agencies struggle to fulfill their mandate of safeguarding public health and ensuring the quality and safety of medications available in the Nigerian market (Ndomondo-Sigonda, et al., 2017; Ncube, et al., 2021; Ekeigwe, 2019).

In conclusion, addressing regulatory challenges in medication quality control requires a multifaceted approach that addresses systemic issues such as inadequate regulatory capacity, inconsistent enforcement mechanisms, the proliferation of substandard and counterfeit medications, limited access to essential medicines, and infrastructural deficiencies. By strengthening regulatory frameworks, enhancing enforcement mechanisms, improving access to quality medicines, and investing in infrastructure development, Nigeria can mitigate the risks associated with poor-quality medications and safeguard the health and well-being of its population.

Analysis of Regulatory Challenges

Each regulatory challenge in medication quality control in Nigeria requires a detailed examination to understand its complexity and implications fully. This involves assessing the extent of inadequate regulatory capacity, inconsistent enforcement mechanisms, the proliferation of substandard and counterfeit medications, limited access to essential medicines, and infrastructural deficiencies. By delving into the specific nuances of each challenge, stakeholders can develop targeted strategies to address underlying issues and improve medication quality control processes (Awele, 2021; Höllein, et al., 2016).

The regulatory challenges in medication quality control have a profound impact on patient safety and public health in Nigeria. Substandard and counterfeit medications jeopardize patient well-being by exposing them to ineffective treatments, adverse reactions, and health complications. Inadequate access to essential medicines further exacerbates health disparities and undermines efforts to combat diseases effectively. Moreover, weak regulatory oversight and enforcement mechanisms erode public trust in the healthcare system, leading to diminished confidence in pharmaceutical products and healthcare services overall (Taylor, et al., 2001; Yakubu, et al., 2020).

Various contributing factors and root causes underlie the regulatory challenges in medication quality control in Nigeria. These may include institutional weaknesses, corruption, insufficient funding, lack of political will, and gaps in regulatory frameworks. Additionally, socioeconomic factors such as poverty, illiteracy, and limited healthcare infrastructure exacerbate the problem by creating opportunities for the proliferation of substandard and counterfeit medications (Yakubu, 2020; Ndichu, et al., 2019). Understanding these underlying factors is essential for devising effective solutions that address systemic issues and promote sustainable improvements in medication quality control.

Solutions to Enhance Medication Quality Control

Implementing comprehensive legislative reforms to strengthen regulatory frameworks and enhance the authority and capacity of regulatory agencies to enforce quality standards effectively (Rodrigo, et al., 2009). Aligning regulatory standards and practices with international best practices to ensure consistency and compatibility with global quality standards, thereby facilitating trade and enhancing consumer protection. Providing specialized training programs and capacity-building initiatives for regulatory personnel to enhance their skills and expertise in medication quality control, regulatory compliance, and enforcement (Glover, et al., 2018). Allocating resources for the establishment and enhancement of laboratory infrastructure, including equipment, facilities, and quality assurance systems, to enable robust quality testing and analysis of pharmaceutical products (Mukherjee, 2019;).

Fostering collaboration and coordination among regulatory agencies at the national, regional, and local levels to enhance information sharing, joint inspections, and enforcement actions against violators of quality standards. Implementing measures to strengthen supply chain management, including traceability systems, inventory control mechanisms, and stringent import and export controls, to prevent the entry and distribution of substandard and counterfeit medications.

Launching public awareness campaigns and educational programs to empower consumers with knowledge about medication quality, safety, and regulatory rights, enabling them to make informed decisions and demand quality-assured products. Establishing channels for reporting suspected cases of substandard and counterfeit medications to regulatory authorities, healthcare providers, and consumer protection agencies, facilitating prompt investigation and enforcement actions against violators.

By implementing these comprehensive solutions, Nigeria can enhance medication quality control, mitigate regulatory challenges, and safeguard patient safety and public health effectively.

Implementation Strategies

The prioritization of solutions for enhancing medication quality control in Nigeria should be guided by the urgency of addressing specific regulatory challenges and the feasibility of implementing proposed interventions. Solutions addressing critical issues with immediate and severe impacts on patient safety and public health should be prioritized. For example, initiatives targeting the proliferation of substandard and counterfeit medications may take precedence due to their significant negative consequences. Feasibility considerations encompass factors such as available resources, regulatory capacity, political will, and stakeholder support. Solutions that can be implemented with existing resources and infrastructure should be prioritized, while more ambitious reforms may require phased implementation and additional support (Awele, 2021).

Developing a clear and realistic timeline for the implementation of solutions is essential for ensuring accountability and measuring progress. The timeline should outline specific milestones, deadlines, and benchmarks for each proposed intervention. Short-term, medium-term, and long-term goals should be established to facilitate gradual progress towards enhancing medication quality control. Prioritized solutions with immediate impact and feasibility should be implemented first, followed by initiatives requiring longer-term planning and investment.

Regular reviews and updates to the implementation timeline may be necessary to accommodate unforeseen challenges and adjust strategies as needed (Queen, et al., 2023).

Effective implementation of solutions requires the allocation of adequate resources and delineation of responsibilities among relevant stakeholders. Financial resources should be allocated to fund priority initiatives, including regulatory capacity-building, infrastructure development, training programs, and public awareness campaigns. Human resources, including regulatory personnel, technical experts, and healthcare professionals, should be mobilized to support implementation efforts. Clear roles and responsibilities should be assigned to regulatory agencies, government agencies, industry stakeholders, healthcare providers, and civil society organizations to ensure coordinated action and accountability. Collaboration and partnerships between public and private sectors, as well as international cooperation, can leverage resources and expertise to enhance medication quality control effectively (Opeyemi, et al., 2024).

Evaluation and Monitoring

Establishing metrics and indicators for assessing the effectiveness of implemented solutions is essential for evaluating progress and identifying areas for improvement. Key performance indicators (KPIs) may include measures of medication quality, such as the prevalence of substandard and counterfeit medications, adherence to regulatory standards, and consumer confidence in pharmaceutical products. Other metrics may focus on regulatory capacity, enforcement outcomes, access to essential medicines, and public awareness levels. Baseline data should be collected prior to implementation to establish benchmarks, and regular monitoring and evaluation should track changes over time. Qualitative feedback from stakeholders and beneficiaries can complement quantitative data to provide a comprehensive understanding of the impact of implemented solutions (Zeitz, et al., 1993; Berendes, et al., 2013).

Continuous monitoring and evaluation are critical for identifying emerging challenges, evaluating the effectiveness of implemented strategies, and making informed adjustments as needed. Regular reviews of progress against established KPIs can inform decision-making and identify areas requiring corrective action. Stakeholder consultations, feedback mechanisms, and periodic assessments can provide valuable insights into the effectiveness of interventions and areas for improvement. Flexibility and adaptability are essential, as regulatory challenges and external factors may evolve over time. Strategies should be responsive to changing circumstances and updated accordingly to ensure ongoing effectiveness in enhancing medication quality control and safeguarding public health. By prioritizing implementation strategies, establishing clear timelines and responsibilities, and implementing robust monitoring and evaluation mechanisms, Nigeria can make significant strides in enhancing medication quality control and improving public health outcomes (NNEOMA, and OBINNA, 2021; Conway, et al., 2013).

Future Outlook

As Nigeria strives to enhance medication quality control, several key trends and developments will shape the future landscape of pharmaceutical regulation and public health. One significant trend is the increasing globalization of the pharmaceutical supply chain. With the expansion of international trade and the growing interconnectedness of markets, regulatory agencies must adapt to oversee the quality and safety of pharmaceutical products imported into Nigeria. Strengthening collaboration with international partners and adopting harmonized regulatory

standards will be crucial in addressing the challenges posed by cross-border trade in medications. Advancements in technology offer opportunities to improve medication quality control processes (Raphael, 2011; Agwu, 2014). The use of blockchain technology, for instance, can enhance transparency and traceability throughout the pharmaceutical supply chain, helping to prevent the entry of substandard and counterfeit medications. Additionally, digital platforms and mobile applications can empower consumers with tools to verify the authenticity of medications and report suspected cases of counterfeit drugs (Sunny, et al., 2020; Liu, et al., 2021).

Furthermore, increasing public awareness and advocacy efforts are essential for sustaining momentum in medication quality control initiatives. Engaging with communities, healthcare providers, and civil society organizations can foster a culture of accountability and demand for quality-assured pharmaceutical products. Empowering consumers with knowledge about medication safety and regulatory rights can amplify the impact of regulatory interventions and contribute to improved health outcomes (Erah, 2011; Fokunang, et al., 2011).

RECOMMENDATIONS AND CONCLUSION

The regulatory challenges in medication quality control in Nigeria, including inadequate regulatory capacity, inconsistent enforcement mechanisms, the proliferation of substandard and counterfeit medications, limited access to essential medicines, and infrastructural deficiencies, necessitate comprehensive solutions. Proposed interventions include strengthening regulatory frameworks, improving regulatory capacity, enhancing enforcement mechanisms, and promoting public awareness and community engagement.

Enhancing medication quality control is paramount for safeguarding public health and promoting the growth and sustainability of the pharmaceutical sector in Nigeria. Quality-assured medications are essential for effective disease management, patient safety, and public trust in the healthcare system. By ensuring the availability of safe and effective pharmaceutical products, Nigeria can improve health outcomes, reduce healthcare costs, and stimulate economic development. Addressing regulatory challenges in medication quality control requires collective action and collaboration among government agencies, regulatory bodies, industry stakeholders, healthcare providers, and civil society organizations. Stakeholders must commit to implementing proposed solutions, allocating resources effectively, and fostering a culture of compliance with regulatory standards. By working together, Nigeria can overcome regulatory challenges, enhance medication quality control, and improve public health outcomes for all its citizens.

In conclusion, prioritizing medication quality control is essential for ensuring access to safe and effective pharmaceutical products and promoting public health in Nigeria. By addressing regulatory challenges, implementing comprehensive solutions, and fostering collaboration among stakeholders, Nigeria can build a robust regulatory framework that safeguards patient safety, fosters pharmaceutical sector growth, and contributes to the overall well-being of its population.

Reference

Afolabi, M.O. (2013). A disruptive innovation model for indigenous medicine research: a Nigerian perspective. *African Journal of Science, Technology, Innovation and Development*, *5*(6), 445-457.

Agwu, M.O. (2014). Organizational culture and employees performance in the national agency for food and drugs administration and control (NAFDAC) Nigeria. *Global Journal of Management and Business Research*, *14*(2), 1-11.

Akinyandenu, O. (2013). Counterfeit drugs in Nigeria: A threat to public health. *African journal of pharmacy and pharmacology*, *7*(36), 2571-2576.

Amadi, C., & Tsui, E.K. (2019). How the quality of essential medicines is perceived and maintained through the pharmaceutical supply chain: A perspective from stakeholders in Nigeria. *Research in Social and Administrative Pharmacy*, *15*(11), 1344-1357.

Awele, A.C. (2021). A comparative study of Regulatory systems and Quality management practices in the manufacturing process of different pharmaceutical companies in Nigeria.

Berendes, S., Adeyemi, O., Oladele, E.A., Oresanya, O.B., Okoh, F., & Valadez, J.J. (2012). Are patent medicine vendors effective agents in malaria control? Using lot quality assurance sampling to assess quality of practice in Jigawa, Nigeria.

Buckley, G.J., & Gostin, L.O. eds. (2013). Countering the problem of falsified and substandard drugs.

Conway, J., Bero, L., Ondari, C., & Wasan, K.M. (2013). Review of the quality of pediatric medications in developing countries. *Journal of Pharmaceutical Sciences*, *102*(5), 1419-1433.

Cyr, M.E., Etchin, A.G., Guthrie, B.J., & Benneyan, J.C. (2019). Access to specialty healthcare in urban versus rural US populations: a systematic literature review. *BMC HEALTH SERVICES RESEARCH*, *19*(1), 1-17.

Diaz, A., Baweja, R., Bonatakis, J.K., & Baweja, R. (2021). Global health disparities in vulnerable populations of psychiatric patients during the COVID-19 pandemic. *World Journal of Psychiatry*, *11*(4), 94.

Dixon, J.R. (1999). The international conference on harmonization good clinical practice guideline. *Quality Assurance*, *6*(2), 65-74.

Douthit, N., Kiv, S., Dwolatzky, T., & Biswas, S. (2015). Exposing some important barriers to health care access in the rural USA. *Public Health*, *129*(6), 611-620.

Efe, S.I. (2013). Health care problem and management in Nigeria. *Journal of Geography and Regional Planning*, *6*(6), 244.

Ekeigwe, A.A. (2019). Drug manufacturing and access to medicines: the West African story. A literature review of challenges and proposed remediation. *AAPS Open*, *5*(1), 3.

Erah, O. (2011). The PharmD program: prospects and challenges in Nigeria. *Nigerian Journal of Pharmaceutical Research*, *9*(1).

Fokunang, C.N., Ndikum, V., Tabi, O.Y., Jiofack, R.B., Ngameni, B., Guedje, N.M., Tembe-Fokunang, E.A., Tomkins, , Barkwan, S., Kechia, F., & Asongalem, E., 2011. Traditional medicine: past, present and future research and development prospects and integration in the National Health System of Cameroon. *African journal of traditional, complementary and alternative medicines*, *8*(3).

Galletly, C.L., & Pinkerton, S.D. (2006). Conflicting messages: how criminal HIV disclosure laws undermine public health efforts to control the spread of HIV. *AIDS and Behavior*, *10*, 451-461.

Garuba, H.A., Kohler, J.C., & Huisman, A.M. (2009). Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers. *Globalization and Health*, *5*, 1-13.

Glover, B., Akinbo, O., Savadogo, M., Timpo, S., Lemgo, G., Sinebo, W., Akile, S., Obukosia, S., Ouedraogo, J., Ndomondo-Sigonda, M., & Koch, M., 2018, July. Strengthening regulatory capacity for gene drives in Africa: leveraging NEPAD's experience in establishing regulatory systems for medicines and GM crops in Africa. In *BMC proceedings* (Vol. 12, No. 8, 19-28). BioMed Central.

György, V.R. (2018). Evaluation of the online pharmaceutical market and counterfeit medicines: Development of a Risk based safety mapping of online pharmaceutical market.

Haji, S.K. (2023). *Poor Accountability and Corruption and its Impact on Quality of Care in the Public Health Sector within the Kurdistan Region of Iraq* (Doctoral dissertation, University of Portsmouth).

Höllein, L., Kaale, E., Mwalwisi, Y.H., Schulze, M.H., & Holzgrabe, U. (2016). Routine quality control of medicines in developing countries: analytical challenges, regulatory infrastructures and the prevalence of counterfeit medicines in Tanzania. *TrAC Trends in Analytical Chemistry*, *76*, 60-70.

Kohler, J.C., Martinez, M.G., Petkov, M., & Sale, J. (2016). Corruption in the pharmaceutical sector: diagnosing the challenges.

Lawrence, X.Y., & Woodcock, J. (2015). FDA pharmaceutical quality oversight. *International Journal of Pharmaceutics*, *491*(1-2), 2-7.

Liang, B.A., & Mackey, T. (2009). Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. *American Journal of Law & Medicine*, *35*(1), 125-184.

Liu, X., Barenji, A.V., Li, Z., Montreuil, B., & Huang, G.Q. (2021). Blockchain-based smart tracking and tracing platform for drug supply chain. *Computers & Industrial Engineering*, *161*, 107669.

Mackey, T.K. (2013). Global health diplomacy and the governance of counterfeit medicines: a mapping exercise of institutional approaches. *Journal of Health Diplomacy*, *1*(1).

Mukherjee, K. (2019). *Quality control and evaluation of herbal drugs: Evaluating natural products and traditional medicine*. Elsevier.

Ncube, B.M., Dube, A., & Ward, K. (2021). Establishment of the African Medicines Agency: progress, challenges and regulatory readiness. *Journal of Pharmaceutical Policy and Practice*, *14*, 1-12.

Ndichu, E.T., Ohiri, K., Sekoni, O., Makinde, O., & Schulman, K. (2019). Evaluating the quality of antihypertensive drugs in Lagos State, Nigeria. *PLoS One*, *14*(2), e0211567.

Ndomondo-Sigonda, M., Miot, J., Naidoo, S., Dodoo, A., & Kaale, E., 2017. Medicines regulation in Africa: current state and opportunities. *Pharmaceutical Medicine*, *31*, 383-397.

Nigeria's, I.W. (2023). Chapter five interaction within Nigeria's pharmaceutical industry Adesina Ayobami Oyewale. *Domestic Production and Procurement of Medicines in Nigeria: Capabilities, Challenges and Prospects*, 47.

Nneoma, O., & Obinna, E. (2021). Development of quality indicators for pharmaceutical care performance assessment in Nigerian community pharmacies: a Delphi panel.

Nsimba, S.E. (2009). Problems associated with substandard and counterfeit drugs in developing countries: A review article on global implications of counterfeit drugs in the era of anti-retroviral (ARVS) drugs in a free market economy.

Obuaku, C. (2014). Essential medicines in Nigeria: foregrounding access to affordable essential medicines. *African Sociological Review/Revue Africaine de Sociologie*, *18*(2), 42-60.

Ogbonna, B.O., Ilika, A.L., & Nwabueze, S.A. (2015). National drug policy in Nigeria, 1985-2015. *World Journal of Pharmacy Research*, *4*(6), 248-264.

Olowofela, A., Fourrier-Réglat, A., & Isah, A.O. (2016). Pharmacovigilance in Nigeria: an overview. *Pharmaceutical Medicine*, *30*, 87-94.

Opeyemi, A.A., Obeagu, E.I., & Hassan, A.O. (2024). Enhancing quality healthcare in Nigeria through medical laboratory services: A review. *Medicine*, *103*(2), e36869.

Pezzola, A., & Sweet, C.M. (2016). Global pharmaceutical regulation: the challenge of integration for developing states. *Globalization and Health*, *12*, 1-18.

Queen, K., Stanislaus, O., & Mary, D. (2023). Patient Safety in Nigerian Health Care Facilities: A Review. *Asian Journal of Medical Principles and Clinical Practice*, *6*(2), 224-232.

Raphael, E.C. (2011). Traditional medicine in Nigeria: current status and the future. *Research Journal of Pharmacology*, *5*(6), 90-94.

Rodrigo, D., Allio, L., & Andres-Amo, (2009). Multi-level regulatory governance: policies, institutions and tools for regulatory quality and policy coherence.

Roth, L., Bempong, D., Babigumira, J.B., Banoo, S., Cooke, E., Jeffreys, D., Kasonde, L., Leufkens, H.G., Lim, J.C., Lumpkin, M., & Mahlangu, G. (2018). Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. *Globalization and Health*, *14*(1), 1-12.

Sunny, J., Undralla, N., & Pillai, V.M. (2020). Supply chain transparency through blockchain-based traceability: An overview with demonstration. *Computers & Industrial Engineering*, *150*, 106895.

Taylor, R.B., Shakoor, O., Behrens, R.H., Everard, M., Low, A.S., Wangboonskul, J., Reid, R.G., & Kolawole, J.A., 2001. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. *The Lancet*, *357*(9272), 1933-1936.

Wilson, M.L., Fleming, K.A., Kuti, M.A., Looi, L.M., Lago, N., & Ru, K. (2018). Access to pathology and laboratory medicine services: a crucial gap. *The Lancet*, *391*(10133), 1927-1938.

World Health Organization, (2000). *Guidelines for the regulatory assessment of medicinal products for use in self-medication* (No. WHO/EDM/QSM/00.1). World Health Organization.

World Health Organization, (2017). WHO Global Surveillance and Monitoring System for substandard and falsified medical products.

Yakubu, O.P. (2020). *An Analysis of Loopholes in the Pharmaceutical Supply Chain, and Methods for Improving Control of Counterfeit Drugs in Nigeria* (Doctoral dissertation, Griffith College).

Yakubu, R., Isa, A.M., Abubakar, I.J., Oreagba, I., & Awaisu, A. (2020). Drug safety in Nigeria. In *Drug Safety in Developing Countries* (pp. 525-556). Academic Press.

Zeitz, S., Salami, C.G., Burnham, G., Goings, S.A., Tijani, K., & Morrow, R.H. (1993). Quality assurance management methods applied to a local-level primary health care system in rural Nigeria. *The International Journal of Health Planning and Management*, *8*(3), 235-244.